Financiere de Tubize SA
XBRU:TUB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
71.7
148
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Financiere de Tubize SA
Financiere de Tubize SA
Change in Working Capital
Financiere de Tubize SA
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Financiere de Tubize SA
XBRU:TUB
|
Change in Working Capital
€146k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ucb SA
XBRU:UCB
|
Change in Working Capital
-€308m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Hyloris Pharmaceuticals SA
XBRU:HYL
|
Change in Working Capital
€2.2m
|
CAGR 3-Years
178%
|
CAGR 5-Years
174%
|
CAGR 10-Years
N/A
|
|
Financiere de Tubize SA
Glance View
Nestled in the heart of Belgium, Financiere de Tubize SA stands as a distinctive player in the world of investment holding companies, anchored in its robust shareholding strategy. Unlike many investment entities that diversify their portfolios across industries, Tubize has channeled its focus largely into the pharmaceutical sector through its significant shareholding in UCB, a global biopharmaceutical giant. This singular focus reflects a strategic commitment to capitalize on the growth and innovations within the healthcare industry, leveraging UCB's extensive research capabilities and expansive market presence. By holding a concentrated position in a company with established credentials in developing treatments for severe diseases, Tubize essentially acts as a conduit for investors to gain exposure to the burgeoning potential of biopharmaceutical advancements. The financial success of Financiere de Tubize SA is intricately tied to the performance of UCB. As UCB thrives and expands through its innovative drug developments and strategic market expansions, Tubize enjoys a consistent flow of dividends and capital appreciation. This dividend income underpins Tubize's operational model, allowing it to reinvest in its core holdings and distribute earnings to its own shareholders, thereby creating a cyclical flow of wealth generation and sustainability. Tubize's approach is akin to a watchful guardian, closely monitoring UCB's strategic paths while maintaining an investment structure that keeps administrative and operational costs minimal. Through such a streamlined focus, Financiere de Tubize SA offers investors a targeted and long-term pathway into the pharmaceutical sector, marked by careful oversight and strategic clarity.
See Also
What is Financiere de Tubize SA's Change in Working Capital?
Change in Working Capital
146k
EUR
Based on the financial report for Jun 30, 2024, Financiere de Tubize SA's Change in Working Capital amounts to 146k EUR.
You don't have any saved screeners yet